ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy

被引：0

作者：

Evans, T. R. Jeffry

Kudo, Masatoshi

Cheng, Ann-Lii

Wyrwicz, Lucjan S.

Ngan, Roger Kc

Blanc, Jean-Frederic

Baron, Ari David

Vogel, Arndt

Ikeda, Masafumi

Piscaglia, Fabio

Qin, Shukui

Hoshi, Taisuke

Tamaki, Ryuji

Funahashi, Yasuhiro

Okpara, Chinyere E.

Sagane, Koji

Xing, Dongyuan

Minoshima, Yukinori

Finn, Richard S.

机构：

[1] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Hong Kong, Hong Kong, Peoples R China

[7] Univ Bordeaux, Bordeaux, France

[8] Sutter Calif Pacif Med Ctr, San Francisco, CA USA

[9] Hannover Med Sch, Hannover, Germany

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy

[12] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[13] Eisai & Co Ltd, Ibaraki, Japan

[14] Eisai Ltd, Hatfield, Herts, England

[15] Eisai Inc, Nutley, NJ USA

[16] UCLA Med Ctr, Geffen Sch Med, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4094

引用

页数：1

共 50 条

[21] A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
Zhu, Andrew X.
Finn, Richard S.
Ikeda, Masafumi
Sung, Max W.
Baron, Ari David
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Shuichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina E.
Saito, Kenichi
Siegel, Abby B.
Dubrovsky, Leonid
Llovet, Josep M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[22] A phase Ib study of lenvatinib plus pembrolizumab (LEN plus PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
Kudo, M.
Finn, R.
Ikeda, M.
Zhu, A.
Sung, M.
Baron, A.
Okusaka, T.
Kobayashi, M.
Kumada, H.
Kaneko, S.
Pracht, M.
Meyer, T.
Nagao, S.
Saito, K.
Mody, K.
Dubrovsky, L.
Llovet, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1402
[23] The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
Trueman, David
Liu, Yifeng
Geadah, Marc
Hon, Nicholas
Sabapathy, Suthakar
Kamboj, Laveena
Li, Huimin
Lucero, Melanie
Meier, Genevieve
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Edeline, Julien
Merle, Philippe
Fang, Weijia
Assenat, Eric
Pan, Hongming
Rimassa, Lorenza
Li, Zhiwei
Blanc, Jean-Frederic
Yen, Chia-Jui
Ross, Paul J.
Hu, Sheng
Zhang, Tao
Tran, Albert
Shao, Guoliang
Bouattour, Mohamed
Chen, Yajin
Wu, John
Li, Bai
Chica-Duque, Sandra
Ren, Zhenggang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[25] Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
Edeline, Julien
Merle, Philippe
Fang, Weijia
Assenat, Eric
Pan, Hongming
Rimassa, Lorenza
Li, Zhiwei
Blanc, Jean-Frederic
Yen, Chia-Jui
Ross, Paul J.
Hu, Sheng
Zhang, Tao
Tran, Albert
Shao, Guoliang
Bouattour, Mohamed
Chen, Yajin
Wu, John
Li, Vincent
Chica-Duque, Sandra
Ren, Zhenggang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, J.
Shepard, K. V.
Finn, R. S.
Ikeda, M.
Sung, M.
Baron, A. D.
Kudo, M.
Okusaka, T.
Kobayashi, M.
Kumada, H.
Kaneko, S.
Pracht, M.
Mamontov, K.
Meyer, T.
Mody, K.
Kubota, T.
Saito, K.
Siegel, A. B.
Dubrovsky, L.
Zhu, A. X.
ANNALS OF ONCOLOGY, 2019, 30
[27] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
Galle, Peter Robert
Decaens, Thomas
Kudo, Masatoshi
Qin, Shukui
Fonseca, Leonardo
Sangro, Bruno
Karachiwala, Hatim
Park, Joong-Won
Gane, Edward
Pinter, Matthias
Tai, David
Santoro, Armando
Pizarro, Gonzalo
Chiu, Chang-Fang
Schenker, Michael
He, Aiwu Ruth
Wang, Qi
Stromko, Caitlyn
Hreiki, Joseph
Yau, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA4008 - LBA4008
[28] A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Ikeda, Masafumi
Sung, Max W.
Kudo, Masatoshi
Kobayashi, Masahiro
Baron, Ari D.
Finn, Richard S.
Kaneko, Shuichi
Zhu, Andrew X.
Kubota, Tomoki
Kralijevic, Silvija
Ikezawa, Hiroki
Siegel, Abby B.
Kumada, Hiromitsu
Okusaka, Takuji
CANCER RESEARCH, 2019, 79 (13)
[29] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Llovet, Josep
Finn, Richard
Ikeda, Masfumi
Sung, Max
Baron, Ari
Kudo, Masatoshi
Okusaka, Takuji
Kobayashi, Masahiro
Kumada, Hiromitsu
Kaneko, Suichi
Pracht, Marc
Mamontov, Konstantin
Meyer, Tim
Mody, Kalgi
Kubota, Tomoki
Dutcus, Corina
Saito, Kenichi
Siegel, Abby
Dubrovsky, Leonid
Young, Louise
Zhu, Andrew X.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
[30] Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
Sun, H-C.
Huang, C.
Zhu, X-D.
Shen, Y-H.
Wu, D.
Ge, N-L.
Chen, Y.
Tan, C-J.
Zhou, J.
Fan, J.
ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308

← 1 2 3 4 5 →